By 2030, it is anticipated that the France Oncology Therapeutics Market will reach a value of $8.8 Bn from $4.9 Bn in 2022, growing at a CAGR of 7.4% during 2022-2030. The Oncology Therapeutics Market in France is dominated by a few domestic pharmaceutical companies such as Bristol Myers Squibb, Boehringer Ingelheim, and CureVac. The Oncology Therapeutics Market in France is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for France Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.
By 2030, it is anticipated that the France Oncology Therapeutics Market will reach a value of $8.8 Bn from $4.9 Bn in 2022, growing at a CAGR of 7.4% during 2022-2030.
France is a developed country in Western Europe with various overseas territories and islands on other continents and in the Indian, Pacific, and Atlantic oceans. Breast oncology was associated with the highest spending (2.1 % of total expenditures) in France among the four particular oncology locations (lung, colorectal, and prostate). In 2019, cancer care accounted for around 12% of overall health spending in France. In 2020, France had an age-standardized incidence rate of oncology of 340 per 100,000 population. In comparison to other European countries, France has a higher cumulative risk of incidence, at 32.7 %. This location has a lower mortality risk of 11.2 % when compared to others.
In France, the four primary sites account for only half of all incident cases: breast cancer in women (59,000 cases), prostate cancer (48,000 cases), lung cancer (49,000 cases), and colon cancer (45,000 cases) in both sexes. 8.1% of cancer deaths are caused by alcohol drinking in men ages 15 years or older. France’s government spent 12.2 % of its GDP on healthcare in 2020.
Market Growth Drivers
The ESMÉ ("Épidémio-Stratégie Médico-Economique") programme, launched in 2014 by Unicancer R&D and sponsored by all French Comprehensive Cancer Centres (FCCCs), is an independent academic project that intends to centralise real-world data from cancer patients in France. France has a talented and productive workforce, as well as an ageing population. Through the Temporary Use Authorization (TUA) system, patients in France benefit from an efficient system of access to innovative drugs. These aspects could boost France's Oncology Therapeutics Market.
Market Restraints
There is no programme for cervical cancer screening or acetic acid visual inspection. Despite efforts to provide equitable access to care in some areas of France, certain shadows linger. These factors may deter new entrants into the France Oncology Therapeutics Market.
Key Players
March 2023: Ono and Macomics collaborate to create cancer therapy. The collaboration will focus on the advancement of cancer treatment using macrophage-targeting antibodies. Macomics, a business specialising in macrophage drug discovery, has announced the start of a global drug discovery collaboration with Ono Pharmaceutical. The team will create new immuno-oncology antibody medicines against a novel macrophage target of relevance in cancer research.
January 2023: Servier and Aqemia have announced an expansion of their joint new-molecule development effort focusing on an intractable immuno-oncology therapeutic target. This expansion maintains the fruitful collaboration between Servier and Aqemia, which began in December 2021 with the goal of using artificial intelligence to accelerate the discovery of therapeutic candidates in the field of immuno-oncology.
In France, the regulatory authority responsible for the approval and regulation of therapeutic products, including cancer therapeutics, is the National Agency for the Safety of Medicines and Health Products (ANSM). In France, the maximum reimbursement level and price for new pharmaceuticals are determined using a cardinal metric system that reflects the added value of the product. In France, the interim authorization for use ATU (Autorisation Temporaire d'Utilisation) programme aims to enable early access to medicines for patients with severe or rare diseases with high unmet demand and no authorised therapeutic alternatives.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Oncology Therapeutics Segmentation
By Application (Revenue, USD Billion):
By Drugs (Revenue, USD Billion):
By Therapy (Revenue, USD Billion):
By Route of Administration (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the France Oncology Therapeutics market will reach a value of $8.8 Bn from $4.9 Bn in 2022, growing at a CAGR of 7.4% during 2022-2030.
In France, the regulatory authority responsible for the approval and regulation of therapeutic products, including cancer therapeutics, is the National Agency for the Safety of Medicines and Health Products (ANSM).
The Oncology Therapeutics Market in France is dominated by a few domestic pharmaceutical companies such as Bristol Myers Squibb, Boehringer Ingelheim, and CureVac.